Pre-seed and seed rounds in MedTech are not early SaaS rounds with a medical coat of paint. Investors writing the first institutional cheques into a medical device company expect to see, on one sheet of paper, a clean intended purpose, a defensible classification under Regulation (EU) 2017/745, a credible clinical evidence plan, a regulatory budget loaded into cost of goods sold rather than bolted on as a fourth line, and a team that can execute against a Notified Body. A deck that does not address these five things is not a MedTech pitch, it is a SaaS pitch in a white coat — and the good MedTech investors will pass on it within the first ten minutes.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • MedTech pre-seed funds a clean regulatory foundation, not a working product. Seed funds the path to clinical evidence and Notified Body engagement. Series A funds the run at CE mark and first commercial pilots.
  • The five things investors actually want to see pre-CE are intended purpose, classification, clinical plan, regulatory budget, and a team with execution credibility against Article 10.
  • Pre-seed in European MedTech typically runs from a few hundred thousand euros to around a million, often blended with non-dilutive grants. Seed is usually in the low single-digit millions, sized to cover 18 to 24 months of runway through the Notified Body process.
  • Valuations are lower than generalist tech at the same headcount because the time to revenue is longer and the regulatory risk is real. A realistic MedTech seed valuation respects that, rather than pretending the company is a SaaS comparable.
  • The most common founder pitching mistake is treating regulation as a small appendix at the back of the deck. A serious MedTech investor reads the regulatory slide first.

The round that was lost in the first ten minutes

A founder Felix worked with walked into a seed meeting with a deck that would have won a SaaS round the same afternoon. Growth curves. A clean product demo. A slide on market size pulled from a consulting report. Two slides on the team. Customer quotes. The regulatory slide was slide nineteen, out of twenty-two, titled "Compliance" and containing three bullet points that together amounted to "CE mark planned for Q3."

The investor — a health-focused seed fund — turned to slide nineteen about four minutes in. Read it. Put the deck down. Asked one question: "What is the intended purpose?" The founder answered with a product description, not a regulatory statement. The investor asked about classification. The founder said "probably Class IIa." The investor thanked them for their time.

The rest of the meeting was a polite wind-down. The investor had already made the decision. Not because the product was bad — the product was good — but because the deck told them the founder did not yet understand the shape of the business they were trying to fund. In MedTech, that is not a flaw the investor corrects for you. It is a flaw that kills the round.

This post is the one Felix wishes every pre-seed and seed MedTech founder had read before their first investor meeting. The good news is that the fixes are not expensive. They are just specific, and they have to be done in the right order.

What pre-seed and seed look like in MedTech vs SaaS

In SaaS, pre-seed often funds a working MVP and early signals of usage. Seed funds the search for product-market fit, and the round closes on traction metrics. The whole cycle — from incorporation to Series A — can run 18 to 24 months and the metrics that matter are growth and retention.

In MedTech, the same rounds fund something completely different. Pre-seed funds the regulatory foundation — intended purpose, classification rationale, conformity assessment route, first QMS scaffolding, early risk management, often the first real conversations with a Notified Body. This is deeply unglamorous work, and it is the work that determines whether the rest of the company has a defensible path to market at all. If the intended purpose is fuzzy and the classification is wrong, no amount of seed money fixes it downstream.

Seed, in MedTech, funds the run to clinical evidence and the engagement with the Notified Body. The team is building the technical file in earnest under Annex II of the MDR, running the clinical evaluation, finishing verification and validation, and preparing for the conformity assessment procedure that corresponds to the device class under Article 51. The round has to be sized for 18 to 24 months of runway — the same structural pre-revenue window we covered in why MedTech startups need more capital than SaaS — because the seed milestone is "ready for or inside the Notified Body process," not "first paying customer."

The difference matters enormously for how rounds are structured. A SaaS seed investor wants to see a growth curve. A MedTech seed investor wants to see a regulatory project plan. The evidence is different, the diligence is different, and the risk profile is different. Founders who pitch one when the investor is looking for the other lose rounds they could have closed.

What investors expect to see — the five things

There are five specific things a serious MedTech investor wants to see before they will take a pre-seed or seed round seriously. Not ten. Five. Get these right and the conversation is real. Miss any of them and the conversation ends politely.

1. A clean intended purpose

The intended purpose is not marketing copy. It is a regulatory statement that follows the definition of a medical device in Article 2(1) of Regulation (EU) 2017/745 and tells the reader, in one or two sentences, exactly what the device does, for whom, in which clinical context, and for what purpose. Every downstream decision — classification, conformity assessment route, clinical evaluation scope, risk management scope, Notified Body engagement — flows from the intended purpose. A vague intended purpose is not a small problem. It is a foundational crack, and experienced investors know it.

The good investors ask for the intended purpose in writing. If the founder cannot produce a clean one-paragraph statement on the spot, the meeting is effectively over. For a deeper treatment of how this single sentence controls everything downstream, see the intended purpose decision that controls classification.

2. A defensible classification

Classification under Annex VIII of the MDR determines the conformity assessment route, the clinical evidence burden, and therefore the cost and timeline of the entire project. "Probably Class IIa" is not a classification — it is a guess. Investors want to see the classification rule applied to the intended purpose, a clear rationale, and an honest acknowledgement of any borderline risk. A founder who has read the rules and can defend the classification against a challenge has done the work. A founder who has not, has not.

3. A credible clinical evidence plan

Clinical evidence is the single biggest unknown in most MedTech seed pitches, and it is where under-prepared founders get into the most trouble. The investor wants to know whether the clinical strategy is literature-based, whether a clinical investigation is required, how long the data generation will take, and how the cost is budgeted. "We will figure out the clinical part later" is not a plan. Later is expensive, and the number of months you lose figuring it out later is exactly the number of months your runway is short.

4. A regulatory budget loaded into cost of goods sold

This is the single line item that separates founders who understand MedTech economics from founders who learned finance from a SaaS playbook. Regulatory cost belongs inside COGS, because it is the cost of being allowed to deliver the product at all. A pre-seed or seed deck that treats "regulatory" as a small line under "other" has told the investor that the founder does not yet know how MedTech unit economics work. We covered this frame in detail in funding a MedTech startup, and it is worth re-reading before the first pitch.

The corollary, which Tibor states flatly: if the honest unit economics with regulatory fully loaded into COGS do not produce a viable business at the price point the founder has in mind, the business model is not viable. That is not a sales problem. It is arithmetic.

5. A team that can execute against Article 10

Article 10 of the MDR sets out the manufacturer obligations — QMS under EN ISO 13485:2016+A11:2021, technical documentation, clinical evaluation, post-market surveillance, vigilance, a person responsible for regulatory compliance (PRRC), and more. Investors want to see that the team either has, or will hire, the capability to execute against those obligations. A founding team without any regulatory muscle is not disqualifying at pre-seed, but it needs a credible plan to acquire the capability — a hire, an advisor, or a clearly identified external partner. Hand-waving at "we will get a consultant later" is not a plan.

The deck slide investors actually care about

If you asked a generalist tech investor which slide matters most, they will usually say the market slide or the traction slide. A serious MedTech pre-seed or seed investor will give a different answer. The slide they actually read first is the one that combines intended purpose, classification, and regulatory pathway on a single page.

That slide, done well, contains:

  • The intended purpose statement, one paragraph, clearly worded.
  • The device class and the classification rule that supports it, with a one-line rationale.
  • The conformity assessment route the founder intends to take.
  • The clinical evidence strategy in one sentence — literature-based, clinical investigation, or a combination.
  • An honest timeline to CE mark from today, not from some optimistic past milestone.
  • The regulatory budget as part of COGS, with the total cost to CE mark called out.

That is six bullets on one slide. If those six bullets are in place and defensible, the rest of the deck matters. If they are not, the rest of the deck does not matter, because the investor has already decided. Put that slide near the front of the deck — not slide nineteen.

How to set valuation realistically

Valuation is where MedTech founders often collide with reality. A founder who has watched SaaS companies at similar headcount raise at generous valuations naturally wants a similar number. The investor, who understands the MedTech timeline, will not offer it — and the honest reason is structural, not personal.

The time to first euro of revenue is longer. The capital required to get there is higher. The regulatory risk is real — a wrong classification or a failed clinical evaluation can add a year to the path. All of this shows up in the valuation the investor is willing to offer. A realistic MedTech seed valuation reflects the actual shape of the business, not the shape the founder wishes it had.

The practical heuristic: anchor your pre-seed and seed valuation to the regulatory milestone the round will achieve, not to a SaaS comparable. A pre-seed that funds a clean regulatory foundation is worth what a regulatory foundation is worth. A seed that funds the path through the Notified Body is worth what that path is worth. Inflate the valuation and the next round becomes impossible — either because the Series A investor cannot justify the step-up, or because the cap table is distorted in ways that no clean-up can fix. For a deeper look at the investor landscape shaping these numbers, see venture capital for MedTech in Europe in 2026.

One caveat worth stating plainly: valuation is not the only term that matters. A higher headline valuation with bad control terms, aggressive liquidation preferences, or a long exclusivity clause is worse than a lower headline valuation with clean terms. Felix has watched more than one founder get talked into a valuation they were proud of and regret every single term underneath it six months later.

Common founder pitching mistakes

Five patterns that repeat in the pre-seed and seed rounds that fail.

Pitching a product, not a regulated business. The founder walks through features, customer interviews, and growth projections and treats the MDR as a compliance footnote. The investor wants to fund a company that can legally deliver a medical device at scale. The founder is pitching something else.

The 2-month MDR delusion, in pitch form. The founder puts a Gantt chart on the deck showing CE mark in two months. The investor knows this is wrong, and now the investor also knows the founder either does not know or is not being straight. Neither is fundable. The honest timeline is covered in how long does CE mark take and every founder should read it before drafting a deck.

Under-budgeting regulatory to make the round look smaller. The temptation is to show a lean round the investor will find easy to say yes to. The cost is that the lean round is not actually enough to reach the next milestone, and the company hits the bridge round trap we covered in why MedTech needs more capital than SaaS. Sophisticated investors can see an under-budgeted round from across the room, and they do not find it easier to say yes — they find it a red flag.

Signing exclusivity clauses during the raise. A pre-seed or seed investor asks for a few months of exclusivity during diligence. The founder, eager to close, signs. The investor takes twice as long as promised, then reduces the terms at the last minute. The founder is out of runway and out of options because they could not talk to anyone else. This is not a hypothetical — it is a pattern Felix has watched drain companies to the edge of bankruptcy. Exclusivity should be short, narrow, and granted only to counter-parties whose ability to close is established.

Hiding the team's regulatory gap instead of addressing it. A founding team with no regulatory experience is not disqualifying at pre-seed, provided the gap is acknowledged and there is a credible plan to close it. Hiding the gap is disqualifying. Good investors will find it in diligence, and the trust damage is worse than the original gap. For a longer discussion of how regulatory capability appears on the team slide, see hiring for MedTech startups.

The Subtract to Ship angle

The Subtract to Ship framework applied to pre-seed and seed fundraising is the same as everywhere else in this book: subtract the work that does not trace to a specific MDR obligation, and keep the work that does. In the context of a fundraise, that means the deck should be ruthlessly stripped of compliance theatre — impressive-sounding frameworks, consultant-branded slides, acronym soup — and built around the five things that actually matter to a serious investor. Intended purpose. Classification. Clinical plan. Regulatory budget in COGS. Team execution against Article 10.

Everything else is optional. Most founders put the optional content up front and bury the load-bearing content at the back. Reverse it. The load-bearing slides are the ones the investor reads first, and the ones that decide the round.

Felix's rule — estimate your real investment and time requirement honestly, then double it — applies to the round size directly. A round sized to the doubled number is the round that survives reality. A round sized to the optimistic number is the round that triggers the bridge trap.

Reality Check — Where do you stand?

  1. Can you write your intended purpose in one paragraph, right now, without looking anything up, in a form that would survive an investor's first question?
  2. Do you know your device class, the specific classification rule under Annex VIII that applies, and the rationale that defends it?
  3. Is your clinical evidence strategy specific — literature-based, clinical investigation, or a combination — and do you know what it costs and how long it takes?
  4. Is regulatory cost loaded into COGS in your financial model, or is it sitting outside as a separate "compliance" bucket?
  5. Could you produce, on a single slide, the intended purpose, classification, conformity assessment route, clinical strategy, timeline, and regulatory budget — and defend every line?
  6. Does your team slide show, honestly, how the MDR Article 10 obligations will be executed — either in-house or through a named partner?
  7. Is the round you are raising sized to the doubled honest cost estimate, or to the optimistic one?
  8. If an investor asked for exclusivity tomorrow, do you have a clear policy on what you will and will not sign?

Frequently Asked Questions

How much should a MedTech pre-seed round be? In European MedTech, pre-seed rounds typically range from a few hundred thousand euros to around a million, often blended with non-dilutive grants. The purpose is to fund the regulatory foundation — intended purpose, classification, early QMS scaffolding, first Notified Body conversations — not a working commercial product. Sizing depends heavily on device class and clinical evidence burden.

What is a realistic MedTech seed round size in Europe? Seed rounds in European MedTech are typically in the low single-digit millions, sized to cover 18 to 24 months of runway through the Notified Body process. The honest test is whether the round covers the time from today to the next defensible milestone — usually CE mark readiness — with buffer for the delays that always happen.

Do MedTech investors expect revenue before a seed round? Not usually for the device itself. A medical device above basic Class I cannot legally generate revenue until it has a CE mark, and CE mark is typically the milestone the seed round funds toward. What investors do want is evidence of demand — letters of intent, clinical advocate relationships, pilot agreements — and a clean regulatory foundation.

How do MedTech investors evaluate the team at pre-seed? They look for domain credibility, regulatory awareness, and execution history. A founding team without regulatory experience is not disqualified, provided the gap is acknowledged and there is a credible plan to close it — a hire, an advisor, or a clearly identified external partner. Hand-waving the regulatory question is a red flag.

What valuation should a MedTech pre-seed or seed target? A realistic MedTech valuation is anchored to the regulatory milestone the round will achieve, not to a SaaS comparable at the same headcount. Inflating the valuation makes the next round harder to raise, because the step-up to Series A becomes difficult to justify when the company is still pre-revenue and pre-CE mark.

Should I take money from a generalist investor or wait for a specialist? You can take generalist money if the investor genuinely understands the MedTech timeline and cost profile. You cannot take generalist money if the investor is expecting SaaS-style growth. The distinction is whether they ask about classification, clinical strategy, and reimbursement in the first meeting. If they do, they understand. If they do not, they will eventually panic — and a panicking investor on a long regulatory timeline is a serious problem.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Article 2(1) (definition of medical device), Article 10 (manufacturer obligations), Article 51 (classification). Official Journal L 117, 5.5.2017.
  2. EN ISO 13485:2016 + A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes.

This post is part of the Funding, Business Models and Reimbursement series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The first round is the round that sets the shape of every round after it. Get the five things right, fund the honest timeline, and the rest of the raise has a chance to work.